Trial · NCT01674621
Results by group185
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 185
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (50 mcg) | General appearance at Screening | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (100 mcg) | General appearance at Screening | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (150 mcg) | General appearance at Screening | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Injection (80 mcg) | General appearance at Screening | 1 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal Placebo (0 mcg) | General appearance at Screening | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (50 mcg) | General appearance at 6 months | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (100 mcg) | General appearance at 6 months | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (150 mcg) | General appearance at 6 months | 1 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Injection (80 mcg) | General appearance at 6 months | 1 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal Placebo (0 mcg) | General appearance at 6 months | 0 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (50 mcg) | Skin at Screening | 28 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (100 mcg) | Skin at Screening | 24 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (150 mcg) | Skin at Screening | 17 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Injection (80 mcg) | Skin at Screening | 14 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal Placebo (0 mcg) | Skin at Screening | 21 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (50 mcg) | Skin at 6 months | 29 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (100 mcg) | Skin at 6 months | 26 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal (150 mcg) | Skin at 6 months | 16 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Injection (80 mcg) | Skin at 6 months | 14 | Participants | |
| Number of Participants With Abnormal Physical Examinations at Screening and End of Treatment (6 Months) | Abaloparatide Transdermal Placebo (0 mcg) | Skin at 6 months | 17 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01674621/results?page=3